BC Innovations | Dec 11, 2018
Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Human sample and mouse studies identified a mAb against misfolded SOD1 that could help treat ALS harboring SOD1 mutations. Screening of memory B cells isolated from healthy elderly volunteers for...
BC Week In Review | Sep 28, 2018
Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Sept. 26, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400...
BC Extra | Sep 26, 2018
Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Wednesday, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400 million...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
BioCentury | Apr 20, 2018
Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
BC Week In Review | Apr 13, 2018
Clinical News

Wilson reports 72-week data Wilson’s disease candidate

Wilson Therapeutics AB (SSE:WTX) reported data from 20 evaluable patients with Wilson’s disease in the extension portion of the 24-week Phase II WTX101-201 trial showing that once-daily oral Decuprate bis-choline tetrathiomolybdate (WTX101) controlled mean nonceruloplasmin-bound...
BC Week In Review | Apr 13, 2018
Company News

Alexion acquires Wilson, adds late-stage asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is acquiring Wilson Therapeutics AB (SSE:WTX) for SEK232 per share in cash, or about SEK7.1 billion ($848 million). The price represents a 70% premium to Wilson's April 10 close of SEK136.20,...
BC Extra | Apr 11, 2018
Company News

Alexion acquires Wilson, adds late-stage asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is acquiring Wilson Therapeutics AB (SSE:WTX) for SEK232 per share in cash, or about SEK7.1 billion ($848 million). The price represents a 70% premium to Wilson's Tuesday close of SEK136.20, before...
BC Week In Review | Feb 23, 2018
Clinical News

Wilson Therapeutics starts Phase III of WTX101 for Wilson's disease

Wilson Therapeutics AB (SSE:WTX) began the Phase III FOCuS trial of decuprate bis-choline tetrathiomolybdate (WTX101) to treat Wilson's disease in patients ages 18 and older. Top-line data from the trial are expected 2H19. The single-blind,...
BC Week In Review | Oct 6, 2017
Clinical News

Wilson reports Phase II extension data for Wilson’s disease candidate

Wilson Therapeutics AB (SSE:WTX) reported data from 22 patients with Wilson’s disease in the extension portion of the 24-week Phase II WTX101-201 trial showing that once-daily oral Decuprate bis-choline tetrathiomolybdate (WTX101) controlled mean nonceruloplasmin-bound copper...
Items per page:
1 - 10 of 28